supportive care products / prevention of bone loss in patients with cancer / other osteoporosis therapies / therapy for breast cancer / healthcare professional / healthcare providers / prevention of osteoporosis / treatment of osteoporosis / therapy for prostate cancer / /
MedicalCondition
metastatic disease / routine neoplastic disease / postmenopausal osteoporosis Question 2a / breast cancer Question 3a / prostate cancer Question 4a / postmenopausal osteoporosis Question 1a / Cancer / advanced cancers / disease / osteoporosis / prostate cancer / breast cancer / cancer receiving hormone ablation / postmenopausal osteoporosis / bone metastases / /
Organization
Advisory Committee for Reproductive Health Drugs / office of Oncology Drug Products / Division of Biologic Oncology Products / Division of Reproductive and Urologic Products / U.S. Food and Drug Administration / /
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. It was current when produced, but is no longer maintained and may